FDA Grants Abemaciclib Breakthrough Status for Refractory Breast Cancer

The FDA has granted the CDK4/6 inhibitor abemaciclib a breakthrough therapy designation as monotherapy for heavily pretreated patients with refractory hormone-receptor-positive advanced breast cancer. http://ift.tt/1Mjw3o4

http://ift.tt/1LavBnE

Filed under: cancer alternative medicine